Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 1 · 50%

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.51 [0.18, 1.4]
5 studies · 1733 participants
Low

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.83 [0.72, 0.96]
12 studies · 24797 participants
High